Search results
Replay wins IND clearance for PRAME T cell cancer therapy
Pharmaceutical Technology via Yahoo Finance· 15 hours agoGenome writing company Replay Bio has had its investigational new drug (IND) application cleared by...
New technique improves T cell-based immunotherapies for solid tumors
Medical Xpress· 11 hours agoScientists from Scripps Research have enhanced an existing immunotherapy by removing the sugar coating surrounding solid tumors—such as in melanoma, breast, and prostate cancer—so T cells can ...
Revolutionizing Cancer Treatment: Key to Prolonging CAR T Cell Life Uncovered
SciTechDaily· 2 days agoFOXO1 is required for T cell memory and is linked to longer-lasting clinical outcomes in CAR T cell ...
Astellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop...
NBC 17 Raleigh· 5 hours agoPoseida is advancing differentiated cell and gene therapies with the capacity to cure certain cancers and rare diseases.
Do cutting-edge CAR-T-cell therapies cause cancer? What the data say
Nature· 2 days agoRegulators have identified around 30 cases of cancer linked to this blockbuster treatment. But is...
Biomarkers identified for successful treatment of bone marrow tumors
Medical Xpress· 6 days agoCAR T cell therapy has proven effective in treating various hematological cancers. In a clinical study, researchers from the University ...
CD70 Antibodies CD70 Targeting Therapies Clinical Trials Market Opportunity Insight
Benzinga· 19 hours agoDelhi, May 01, 2024 (GLOBE NEWSWIRE) -- Global CD70 Targeting Therapies Market Opportunity & Clinical Trials Insight 2024 Report Highlights: CD70 Targeting Therapies In Clinical Trials: > 20 TherapiesCD 70
FAS signalling pathway is crucial for CAR T cell persistence - Nature Reviews Immunology
Nature· 6 days agoChimeric antigen receptor (CAR) T cell therapies have revolutionized the treatment of B cell and other malignancies, but the limited persistence of CAR ...
Cell and gene therapy companies trip at scalability hurdle
Pharmaceutical Technology via Yahoo Finance· 3 days agoSince then, major strides have been made in the cell therapy space. The first chimeric antigen...
IN8bio Doses First Patient in Phase 2 Clinical Trial of INB-400 in Newly Diagnosed Glioblastoma -...
Benzinga· 2 days agoNEW YORK, April 30, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (NASDAQ:INAB), a clinical-stage biopharmaceutical company advancing innovative gamma-delta T cell